Pharmafile Logo
Pharmafocus logo
Advanced Search

LEE011

Showing 3 posts of 3 posts found.

novartis_building

Breakthrough therapy designation for Novartis in advanced breast cancer treatment

August 3, 2016
Research and Development, Sales and Marketing Breakthrough Therapy Designation, FDA, LEE011, Novartis, ribociclib

Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …

News
sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016
Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …

News

Pfizer breast cancer pill gets FDA nod

October 14, 2014
Research and Development, Sales and Marketing FDA, Femera, LEE011, Pfizer, bemaciclib, breast cancer, palbociclib

Pfizer’s experimental breast cancer drug palbociclib has been accepted and granted a priority review by the US Food and Drug …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025